A new statistical models shed light on why some patients can extend the dosing interval with Eylea (aflibercept) from 8 weeks ...

Researchers assessed the efficacy of aflibercept 8 mg vs conventional 2 mg doses at 96 weeks in patients with diabetic ...

Subgroup analyses of the PHOTON trial show visual acuity gains across subgroups by race, baseline visual acuity and retina ...

Regeneron Pharmaceutical (NASDAQ:REGN) fell 2% after a court rejected its request for a temporary injunction blocking sales ...

At the GRx+Biosims 2024 conference, panelists explored challenges and progress in biosimilar interchangeability regulations ...

While adverse events (AEs) were reported for 97% of trial participants, such cases were predominantly mild to moderate.

Regeneron Pharmaceuticals Inc. (REGN) announced positive three-year (156-week) data for EYLEA HD (aflibercept) Injection 8 mg from an ...

CHICAGO, CA, UNITED STATES, October 18, 2024 /EINPresswire / -- The Global Age-Related Macular Degeneration (AMD) <a target=_blank href= ...

The most pressing challenges include the financial and emotional burdens associated with frequent, long-term treatments for ...

The global Retinal Vein Occlusion (RVO) treatment market was valued at approximately USD 2.65 billion in 2023 and is projected to exhibit a compound annual growth rate (CAGR) of 6.92% over the ...